Latest news with #NeerajAgrawal
Business Wire
30-06-2025
- Business
- Business Wire
Levelpath Raises $55+ Million to Reimagine Enterprise Procurement, led by Battery Ventures
SAN FRANCISCO--(BUSINESS WIRE)-- Levelpath, the leading AI-native procurement platform, today announced $55+ million in Series B funding led by Battery Ventures, bringing the total raised to $100 million. The new capital accelerates Levelpath's mission to reinvent how global enterprises manage procurement, typically the second-largest operational expense after payroll. Other investors participated in the funding round as well, including Redpoint Ventures, Benchmark, 01A, New View Capital and World Innovation Lab. As part of the funding, Battery Ventures General Partner Neeraj Agrawal will join Levelpath's board of directors alongside representatives from existing investors. Agrawal, who has made multiple appearances on the Forbes Midas List and coined the "T2D3" growth paradigm for SaaS businesses, previously led Battery's investment in Coupa, a leading spend management platform that went public in 2016 and was acquired for approximately $8 billion in 2023. "Levelpath represents the future of enterprise procurement: intelligent, automated, and strategically aligned with business objectives," said Agrawal. "The team has built remarkable technology that delivers demonstrable value to some of the world's largest companies. We are excited to partner with them as they scale to become the definitive procurement platform for global enterprises." Solving the $13 Trillion Procurement Challenge Procurement is the second-largest business expense after payroll, yet it remains one of the least modernized functions in the enterprise. With Levelpath's proprietary Hyperbridge reasoning engine at its core, the platform delivers intelligent automation through true AI-native design, unlocking capabilities that legacy solutions built before 2022 are architecturally challenged to efficiently support. For decades, procurement has been trapped by systems designed for yesterday's problems. Complex interfaces. Endless workflows. Frustrated users. Levelpath changes everything with the first truly AI-native procurement platform built from the ground up for the modern enterprise. "Procurement touches every part of a business, yet it's been held back by tools that fight against you instead of working with you," said Alex Yakubovich, Co-founder and CEO of Levelpath. "We didn't retrofit old systems with AI. We reimagined what procurement could be when intelligence is built into every interaction." Since launching its flagship platform after raising $44.5 million across Benchmark-led Seed and Redpoint-led Series A rounds, Levelpath has built momentum as the 'next chapter' of procurement modernization, offering a sleek, AI‑native experience that delivers speed, transparency and ROI at scale. Fueling Rapid Growth and Market Expansion With Levelpath's AI Agents, procurement teams do not just keep up with the AI wave, they lead it. Levelpath's AI Agents are ushering in a new era of intelligent procurement with autonomous, strategic AI capabilities embedded directly into the platform. The AI Agents are enriched with supplier-centric context and designed to connect insights across critical processes. At their core, Levelpath's AI Agents are designed to act autonomously and proactively on behalf of users, solving real procurement challenges such as sourcing event creation, supplier onboarding, and risk assessments to drive exponential productivity. These AI Agents do not simply support rigid and fragile task automation; they deliver smarter workflows, faster deployment, and predictable outcomes from day one. With preconfigured agents available out of the box, teams can immediately benefit from enhanced decision-making and operational efficiency without the need for complex IT support. Powered by Hyperbridge, Levelpath's AI-native architecture, these AI Agents unify model grounding, context management, and orchestration while ensuring secure, compliant data handling. By identifying the relevant business context, routing queries to the most suitable large language models, and tailoring outputs to specific organizational needs, Levelpath empowers procurement teams to achieve greater efficiency and impact, with fewer resources. This foundation enables organizations to benefit from rapid AI innovation without the need for constant due diligence on the models or integrations themselves. With the launch of Levelpath's AI Agents, the company is doubling down on its core mission: to modernize one of the most critical and overlooked business functions with technology that is both intelligent and delightful. As enterprises face mounting pressure to streamline procurement AI-native tools like Levelpath Agents are poised to become essential infrastructure. Levelpath will use the new funding to accelerate product development, scale its go-to-market team and deepen ecosystem partnerships, all in service of meeting growing enterprise demand for AI-native procurement. With strong early traction and strategic integrations like its placement in Coupa's App Marketplace, Levelpath is well-positioned to make delightful, intelligent procurement the new enterprise standard. "AI is transforming how enterprises operate, and procurement is no exception," said Stan Garber, Co-founder and President of Levelpath. "We're not just building procurement tools, we're building the intelligent infrastructure that turns procurement into a competitive edge that will radically accelerate productivity at scale." Levelpath is now offering a monthly AI Masterclass webinar series to help leaders scale their impact, streamline operations, and accelerate their careers. Follow along to see how to operationalize AI across your business and power real-world procurement workflows. To learn more about Levelpath's AI-native procurement platform, visit About Levelpath Levelpath is the leading AI-native procurement platform transforming how global enterprises manage indirect spend. Built from the ground up for the AI era, our platform unifies procurement operations through intelligent automation, featuring an intuitive stakeholder interface, advanced workflow orchestration, and our proprietary Hyperbridge reasoning engine that delivers real-time intelligence and complete visibility across all procurement activities. Trusted by leading Fortune enterprises worldwide, including Ace Hardware, Amgen, Coupang, Fortrea, GATX, SiriusXM, SSM Health, and Western Union, Levelpath's AI-native architecture enables organizations to collaborate smarter, operate faster, and scale procurement operations that drive measurable business value. Headquartered in San Francisco, Levelpath is backed by Battery, Benchmark, Redpoint Ventures, 01A, Menlo Ventures, NewView Capital, and World Innovation Lab. Learn more at or connect with us on LinkedIn.
Time Business News
26-06-2025
- Business
- Time Business News
A2N Advisory Expands Bookkeeping Services for U.S. Businesses, Led by CA Neeraj Agrawal
NOIDA, INDIA – June 26, 2025 – A2N Advisory, a leading financial company co-founded by experienced accountant Neeraj Agrawal, today announced a major push to offer outsourced bookkeeping services to companies in the United States. This big step aims to give U.S. businesses excellent, affordable, and efficient ways to manage their money, using India's skilled workforce. This move comes as more U.S. businesses look to save money and make their financial records more accurate by having experts handle common but important tasks. CA Neeraj Agrawal explained A2N Advisory's goal to help American companies. 'Our expansion into the U.S. market is a direct response to the growing need for reliable and affordable accounting help,' Agrawal said. 'We offer U.S. companies big benefits like significant cost savings, access to many skilled accountants who understand U.S. financial rules (US GAAP), and the chance for their own teams to focus on business growth and future plans.' A2N Advisory uses strong methods to provide great service. The company's team includes highly qualified accounting professionals, like Chartered Accountants, who know a lot about both U.S. and Indian accounting practices. This ensures that when businesses choose to outsource bookkeeping from USA to India with A2N Advisory, they get services that are very accurate and follow all rules. Using the latest technology and keeping data safe are top priorities for A2N Advisory. The company uses modern cloud-based accounting software for easy, real-time access to financial information and smooth communication. Also, strict security measures, like strong data encryption, secure servers, and tight privacy agreements, are in place to protect sensitive client financial details. A2N Advisory has a proven track record of success with its current U.S. clients. While specific client names are kept private, companies have consistently praised A2N Advisory for their careful work and helpful reports. Clients often highlight the firm's 'clear approach and reporting,' which gives them 'valuable insights into their financial health.' A2N Advisory believes this success comes from focusing on the client and acting like a natural extension of their finance department. The expanded services for U.S. businesses include a full range of solutions: Managing bills to pay (accounts payable) and money owed (accounts receivable) Keeping the main accounting records (general ledger maintenance) Matching bank statements (bank reconciliation) Preparing financial reports Helping with payroll Support for tax preparation All these services are carefully customized to fit the specific needs and rules of each client. A2N Advisory's strong focus on the U.S. market shows its role as a global provider of financial advice, dedicated to helping its international clients grow and stay financially stable. TIME BUSINESS NEWS
The Hindu
09-06-2025
- Business
- The Hindu
Advent to invest $175 million in Felix Pharma to acquire minority stake
Advent, a private equity investor, has announced that funds managed by it have signed a definitive agreement to invest $175 million via primary and secondary capital for a significant minority stake in Dublin, Ireland-based Felix Pharmaceuticals Pvt. Ltd. (Felix), a global Gx animal pharma player. Felix Pharma is one of the developers and manufacturer of off-patent medicines for companion animals. Felix develops, manufactures and supplies to distributors and other branded Gx players for private labelling, particularly in the U.S. Shweta Jalan, Managing Partner, Advent, said, 'Healthcare has been a long-standing focus for us, and strong parallels we see between success in human Gx globally and emerging opportunity in animal health Gx. Felix is well positioned to lead this space with its strong leadership, broad portfolio, and robust R&D and commercial capabilities.' 'Its rapid growth and high customer satisfaction make it a differentiated platform, and we are excited to support Neeraj and the Felix team in scaling it into a global franchise,' she added, Founded in 2015 by Neeraj Agrawal, a McKinsey alum, Sir Jonathan Symonds, Chair of GSK and with 30 years of experience in global pharmaceuticals, and Dr. Shumeet Banerji, ex-CEO of Booz-Allen, Felix said it has pursued strategic growth through a disciplined approach, While the company achieved its first U.S. FDA approval in 2020, it has quickly scaled to a 14 commercialised product portfolio and has several others in advanced stages of pipeline. It has a USFDA-approved oral solid facility dedicated to animal health products and an injectable facility that is expected to be ready by Q3 2025. Neeraj Agrawal, Co-Founder, Felix Pharma, said, 'As we scale in a fast-evolving market, we were looking for a partner who brings not just capital, but also deep operating expertise and the right mindset and networks to help us grow faster and stronger. Advent's strong track record in healthcare and pharma, and their close involvement in building strong businesses, gives us great confidence.'
Economic Times
09-06-2025
- Business
- Economic Times
Advent International to acquire stake in Felix Pharmaceuticals
Advent International, a leading global private equity investor, signed a definitive agreement to invest $175 million via primary and secondary for a significant minority stake in Dublin-headquartered Felix Pharmaceuticals, a leading global generic animal pharma player, stated a company release. Felix Pharma is a manufacturer of off-patent medicines for companion animals. Felix develops, manufactures and supplies to distributors and other branded generic players for private labelling, particularly in the US. With a portfolio of 14 approved products from USFDA and many more under review and development, Felix has the widest portfolio of products in the industry. 'Felix is well positioned to lead this generic space with its strong leadership, broad portfolio, and robust R&D and commercial capabilities. Its rapid growth and high customer satisfaction make it a differentiated platform, and we are excited to support Neeraj and the Felix team in scaling it into a global franchise,' said Shweta Jalan, Managing Partner at Advent. Felix was founded in 2015 by Neeraj Agrawal, Sir Jonathan Symonds and Dr Shumeet Banerji, ex-CEO of Booz-Allen. While the company achieved its first US FDA approval in 2020, marking a pivotal step in its expansion, it has quickly scaled to a 14 commercialised product portfolio and has several others in advanced stages of pipeline, it said. It has a USFDA approved oral solid facility dedicated for animal health products and an injectable facility that is expected to be ready by Q3 2025. Neeraj Agrawal, Co-Founder of Felix Pharma, said, 'As we scale in a fast-evolving market, we were looking for a partner who brings not just capital, but also deep operating expertise and the right mindset and networks to help us grow faster and stronger.'
Time of India
09-06-2025
- Business
- Time of India
Advent International to acquire stake in Felix Pharmaceuticals
Advent International , a leading global private equity investor , signed a definitive agreement to invest $175 million via primary and secondary for a significant minority stake in Dublin-headquartered Felix Pharmaceuticals , a leading global generic animal pharma player, stated a company release. Felix Pharma is a manufacturer of off-patent medicines for companion animals. Felix develops, manufactures and supplies to distributors and other branded generic players for private labelling, particularly in the US. With a portfolio of 14 approved products from USFDA and many more under review and development, Felix has the widest portfolio of products in the industry. 'Felix is well positioned to lead this generic space with its strong leadership, broad portfolio, and robust R&D and commercial capabilities. Its rapid growth and high customer satisfaction make it a differentiated platform, and we are excited to support Neeraj and the Felix team in scaling it into a global franchise,' said Shweta Jalan, Managing Partner at Advent. Felix was founded in 2015 by Neeraj Agrawal, Sir Jonathan Symonds and Dr Shumeet Banerji, ex-CEO of Booz-Allen. While the company achieved its first US FDA approval in 2020, marking a pivotal step in its expansion, it has quickly scaled to a 14 commercialised product portfolio and has several others in advanced stages of pipeline, it said. It has a USFDA approved oral solid facility dedicated for animal health products and an injectable facility that is expected to be ready by Q3 2025. Neeraj Agrawal, Co-Founder of Felix Pharma, said, 'As we scale in a fast-evolving market, we were looking for a partner who brings not just capital, but also deep operating expertise and the right mindset and networks to help us grow faster and stronger.'
